News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Phase II trial of functional imaging-optimized stereotactic fractionated radiotherapy plus temozolomide for recurrent high-grade glioma.



Website: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-00474,00.asp

Posted on: 06/08/2004

Phase II trial of functional imaging-optimized stereotactic fractionated radiotherapy plus temozolomide for recurrent high-grade glioma.

Meeting: 2004 ASCO Annual Meeting
Category: Central Nervous System Tumors
SubCategory: CNS Tumors

Abstract No: 1552
Author(s): C. Nieder, N. Wiedenmann, S. Stark, A. L. Grosu; Klinikum Rechts der Isar, Munich, Germany

Abstract:
Background: Stereotactic fractionated radiotherapy (SFRT) is a valuable treatment option for recurrent high-grade glioma. Its therapeutic ratio might be improved by functional imaging-optimized treatment planning. After this approach has been evaluated in 16 patients, additional chemotherapy with temozolomide was added to the regimen in a single-institution phase II trial.
Methods: 16 patients entered the SFRT alone trial, 30 patients received SFRT plus temozolomide. For treatment planning with the BrainLAB system, the gross tumor volume was defined by C11-methionine PET/CT/MRI image fusion. Maximum diameter was less than 4 cm. Mean age was 50 years. 37 patients had glioblastoma multiforme, 8 anaplastic astrocytoma and 1 anaplastic oligodendroglioma. Previous radiotherapy dose was 54-60 Gy (median interval to retreatment 17 months). Total dose was 30 Gy in 6 fractions. Temozolomide 200 mg/m2/day every 28 days was started before SFRT with 1-2 cycles. After SFRT, 4+ cycles were added. Patients were followed with MRI or CT every other cycle. Results: Median survival was 11 months for patients who received SFRT plus temozolomide and 6 months for patients treated with SFRT alone (p=0.02). No acute neurologic toxicity grade II or higher was observed. No grade IV hematologic toxicity was observed. Signs of radionecrosis were observed in 3 patients. However, surgical resection revealed both tumor and necrosis.

Conclusions: This is the first study of functional imaging-optimized SFRT plus temozolomide. It demonstrates the feasibility and safety of this approach. Our institutional retrospective comparison suggests a significant survival advantage from combined modality treatment which needs to be confirmed prospectively.


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites